ArticleMolecular biotechnology2026
Prognostic and Immunologic Characteristics of Head and Neck Squamous Cell Carcinoma Based on Disulfidptosis-Related lncRNAs.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Disulfidptosis: A Metabolic Cell Death Mechanism with Therapeutic Potential in Cancer.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Disulfidptosis is a new and unique mode of cell death in malignant tumors that plays an important role in tumorigenesis and development. This study aimed to investigate the prognostic value of disulfideptosis-related lncRNAs (DRLs) in head and neck squamous cell carcinoma (HNSCC). Differential expression and Pearson correlation analyses were used to identify DRLs associated with HNSCC, and a regression model containing six core DRLs was constructed using univariate Cox regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis. The predictive power of the models was assessed using Kaplan-Meier analysis, receptor operating characteristic curves (ROC), principal component analysis (PCA), nomograms, and consistency indices. In addition, the relationship between the immune microenvironment of HNSCC and risk prognostic modeling was investigated by functional enrichment using Gene Ontology (GO), Kyoto encyclopedia of genes and genomes (KEGG), single-sample genome enrichment analysis (ssGSEA), and GSEA. Finally, potentially effective drugs for the treatment of HNSCC were identified by immune checkpoint and drug sensitivity screening. In addition, the expression of DRGs and DRLs was assessed using RT-qPCR and protein blotting analysis. A risk score model consisting of six DRLs (MIR34AHG, RAB11B-AS1, SNHG16, AC108693.2, AC090587.1, and AL590617.2) was constructed, which can be used to guide the prognosis and immune microenvironment of HNSCC. According to the survival analysis, high-risk patients had a poorer prognosis. GO and KEGG analyses showed enrichment of DRLs and immune-related pathways. The differential expression of disulfide-related genes (DRGs) and DRLs in HNSCC and adjacent normal tissues was further confirmed by qPCR and protein blotting analysis. Our study elucidated the relationship between DRLs and the prognosis, immune microenvironment, tumor mutation burden (TMB), and drug sensitivity of HNSCC and provided new ideas for individualized treatment of HNSCC.
Indexed as
Identifiers
40716016What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.